Abstract:Background and Objectives Traumatic encephalopathy syndrome (TES) has overlapping clinical symptoms with Alzheimer disease (AD). AD pathology commonly co-occurs with chronic traumatic encephalopathy (CTE) pathology. There are currently no validated CTE biomarkers. AD-specific biomarkers such as plasma P-tau181 and P-tau217 may help to identify patients with TES who have AD pathology. Methods We measured plasma P-tau181 and P-tau217 (Meso Scale Discovery electrochemiluminescence) in patients with TES, mild cognitive impairment/dementia with biomarker-confirmed AD ("AD"), and healthy controls ("HC"). Patients underwent amyloid-beta (Aβ)-PET and a subset underwent tau-PET using [18F]Flortaucipir. We compared plasma P-tau levels controlling for age and sex and also performed AUC analyses to evaluate the accuracy of group differentiation. In patients with TES, we evaluated associations between plasma P-tau, years of repetitive head impact exposure, and tau-PET. Four TES patients with autopsy-confirmed CTE were described qualitatively. Results The sample included 131 participants (TES, N = 18; AD, N = 65; HC, N = 48). Aβ(+) patients with TES (N = 10), but not Aβ(−) TES, had significantly higher plasma P-tau levels than HC (P-tau181: p < 0.001, d = 1.34; P-tau217: p < 0.001, d = 1.59). There was a trend for Aβ(+) TES having higher plasma P-tau than Aβ(−) TES (P-tau181: p = 0.06, d = 1.06; P-tau217: p = 0.09, d = 0.93). AUC analyses showed good classification of Aβ(+) TES from HC for P-tau181 (AUC = 0.87 [0.71–1.00]) and P-tau217 (AUC = 0.93 [0.86–1.00]). Plasma P-tau217 showed fair differentiation of Aβ(+) TES from Aβ(−) TES (AUC = 0.79 [0.54–1.00], p = 0.04), whereas classification accuracy of P-tau181 was slightly lower and not statistically significant (AUC = 0.71 [0.46–0.96], p = 0.13). Patients with AD had higher tau-PET tracer uptake than Aβ(+) TES and were well differentiated using P-tau181 (AUC = 0.81 [0.68–0.94]) and P-tau217 (AUC = 0.86 [0.73–0.98]). Plasma P-tau correlated with the tau-PET signal in Aβ(+) TES but not in Aβ(−) TES, and there was no association between plasma P-tau and years of repetitive head impact exposure. TES patients with severe CTE and no AD at autopsy had low P-tau181 and P-tau217 levels. Discussion Measuring P-tau181 and P-tau217 in plasma may be a feasible and scalable fluid biomarker for identifying AD pathology in TES. Low plasma P-tau levels may be used to increase clinical suspicion of CTE over AD as a primary pathology in TES. Currently, there is no support for P-tau181 or P-tau217 as in vivo biomarkers of CTE tau. Larger studies of patients with pathologically confirmed CTE are needed. Classification of Evidence This study provides Class III evidence that (1) among patients with TES and abnormal Aβ-PET scans, elevated plasma P-tau can differentiate between affected individuals and HCs; (2) low plasma P-tau may help identify patients with TES who do not have Alzheimer; and (3) plasma P-tau181 and P-tau217 are not useful biomarkers of patients with TES who do not have AD.

Spectral behavior of hydrated sulfate salts: implications for Europa mission spectrometer design.

Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players

Alopecia in calves associated with milk substitute feeding

Tau Positron Emission Tomography and Neurocognitive Function Among Former Professional American-Style Football Players

Myocardial infarction: changing sex ratio and other factors; an epidemiological study of acute myocardial infarction based on the experiences of Barnes Hospital for forty-five years.

Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer's disease

Brain morphometry in former American football players: Findings from the DIAGNOSE CTE research project

Examination of plasma biomarkers of amyloid, tau, neurodegeneration, and neuroinflammation in former elite American football players

Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project

Cavum Septum Pellucidum in Former American Football Players: Findings From the DIAGNOSE CTE Research Project

International Consensus on the Use of Tau PET Imaging Agent 18F-Flortaucipir in Alzheimer's Disease.

Gene Transfer Test, Global Rules Approved

Association of Vascular Risk Factors and CSF and Imaging Biomarkers With White Matter Hyperintensities in Former American Football Players

Clinicopathological Evaluation of Chronic Traumatic Encephalopathy in Players of American Football

Clinical and Neuropathological Correlates of Substance Use in American Football Players

Inhibitory effect of zinc ions on platelet aggregation and serotonin release reaction.

Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology

Neuroimaging Biomarkers of Chronic Traumatic Encephalopathy: Targets for the Academic Memory Disorders Clinic

Genome-wide scan of Flortaucipir PET levels finds associated with cerebral tau deposition

Inflammatory biomarkers for neurobehavioral dysregulation in former American football players: findings from the DIAGNOSE CTE Research Project

Cognitive, functional, and neuropsychiatric correlates of regional tau pathology in autopsy-confirmed chronic traumatic encephalopathy